Delve into the hidden innovation system of drug repurposing. When patents expire and commercial value fades, a new wave of ...
MFN pegs US net prices to the second-lowest net price in an eight-country basket, using rebate-inclusive definitions to limit list-price inflation and rebate-based circumvention. Prospective MFN for ...
MarketScan data showed 97% of drug–form–strength combinations were available via MCCPDC; savings estimates assumed a $5.25 shipping fee per drug, likely understating net savings. Cost advantages ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results